Aug. 15 at 3:59 PM
$ABCL Just a reminder from Yahoo Finance:
On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, AbCellera receives
$28 million upfront and is eligible for future preclinical, regulatory, and commercial milestone payments, as well as tiered royalties on net sales.
